NCT00001090View on ClinicalTrials.gov

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1999

Conditions
HIV Infections
Interventions
BIOLOGICAL

APL 400-047

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

DRUG

Sargramostim

Trial Locations (4)

14642

Univ. of Rochester AVEG, Rochester

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

Unknown

JHU AVEG, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH